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ABSTRACT 
 
Acute Myeloid Leukemia (AML) is a disease that occurs when genomic changes alter 
expression of key genes in myeloid blood cells. These changes cause them to resume an 
undifferentiated state, proliferate, and maintain growth throughout the body. AML is commonly 
treated with chemotherapy, but recent efforts to reduce therapy toxicity have focused on drugs 
that specifically target and inhibit protein products of the cancer’s aberrantly expressed genes. 
This method has proved difficult for some proteins because of structural challenges or mutations 
that confer resistance to therapy.  One potential method of targeted therapy that circumvents 
these issues is the use of small molecules that stabilize DNA secondary structures called G-
quadruplexes. G-quadruplexes are present in the promoter region of many potential oncogenes 
and have regulatory roles in their transcription. This study analyzes the therapeutic potential of 
the compound GQC-05 in AML. This compound was shown in vitro to bind and stabilize the 
regulatory G-quadruplex in the MYC oncogene, which is commonly misregulated in AML. 
Through qPCR and western blot analysis, a GQC-05 mediated downregulation of MYC mRNA 
and protein was observed in AML cell lines with high MYC expression. In addition, GQC-05 is 
able to reduce cell viability through induction of apoptosis in sensitive AML cell lines. Concurrent 
treatment of AML cell lines with GQC-05 and the MYC inhibitor (+)JQ1 showed an antagonistic 
effect, indicating potential competition in the silencing of MYC.  However, GQC-05 is not able to 
reduce MYC expression significantly enough to induce apoptosis in less sensitive AML cell lines. 
This resistance may be due to the cells’ lack of dependence on other potential GQC-05 targets 
that may help upregulate MYC or stabilize its protein product. Three such genes identified by 
RNA-seq analysis of GQC-05 treated cells are NOTCH1, PIM1, and RHOU. These results 
indicate that the use of small molecules to target the MYC promoter G-quadruplex is a viable 
potential therapy for AML. They also support a novel mechanism for targeting other potentially 
key genetic drivers in AML and lay the groundwork for advances in treatment of other cancers 
driven by G-quadruplex regulated oncogenes.  
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Chapter 1: Introduction 
1.1 Acute Myeloid Leukemia  
1.1.1 Overview 
Acute leukemia is a malignancy that results from genetic damage and aberrant gene 
expression in blood cells, and it is the most common type of cancer in children (Tarlock and 
Cooper, 2016). A subset of this disease, Acute Myeloid Leukemia (AML), forms when blood cell 
precursors of myeloid lineage are unable to differentiate and begin to proliferate in excess. The 
cancer cells expand in the bone marrow and displace the normal blood cell progenitors. This 
causes disease through inhibition of blood cell production, as well as eventual metastasis and 
displacement of other essential organs.   
1.1.2 Current Treatments 
AML is currently treated by administering chemotherapy agents, such as cytarabine and 
anthracyclines (Tarlock and Cooper, 2016). Cytarabine is a cytosine analog with an arabinose 
sugar in place of deoxyribose. Presence of cytarabine in a cell brings DNA synthesis to a halt 
when DNA Polymerase attempts to integrate it into the growing DNA strand and is stalled by the 
difference in structure of the nucleoside’s sugar (Galmarini et al., 2001). This can be effective 
against rapidly dividing cancer cells, but will also be detrimental to other rapidly dividing cells, 
such as blood cells, hair follicles, and the cells lining the gastrointestinal tract. Loss of these 
normal tissues can give patients nausea, anemia, bleeding, and alopecia (Tarlock and Cooper, 
2016). Anthracyclines are a class of compound that damage the DNA through multiple 
mechanisms including intercalation into the DNA that leads to topoisomerase II-mediated double 
stranded breaks and the production of free radicals that damage DNA structure (Hortobágyi, 
1997).  The DNA damage is used to target replicating cells by clogging up DNA replication 
machinery. In addition to the previously listed side effects of targeting cell replication, 
anthracyclines can also induce heart failure because of the free radicals they produce 
(Hortobágyi, 1997). Both compounds are harsh on patients but effective in killing leukemia cells. 
However, because both compounds inflict heavy damage on the patients’ DNA, it is possible that 
secondary cancer can occur. Furthermore, approximately 30% of patients experience relapse 
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after treatment, usually returning to the clinic with a poor prognosis (Tarlock and Cooper, 2016). 
The high rate of relapse in AML patients and toxicity of commonly used therapies highlight a 
strong need for improved AML therapies that will combat drug resistance and minimize side 
effects.  
1.2 Targeting the MYC Oncogene 
1.2.1 MYC Upregulation in AML 
One method of treating patients with cancer that minimizes side effects is the use of 
compounds that inhibit the gene product or products that are misregulated in the cancer being 
treated. AML is associated with a number of genetic drivers that could serve as targets. One gene 
that is being investigated as a novel target in AML therapies is the transcription factor c-Myc. This 
protein regulates many hallmarks of cancer such as cell growth, proliferation, cell-cycle, 
apoptosis, and cell differentiation (Vita and Henriksson, 2006). Its involvement in many pathways 
makes it a potent oncogene when misregulated.  Many of the gene fusions common in AML (e.g. 
FLT3-ITD (Gilliland and Griffin, 2002), AML1-ETO, PML/RARa, and PLZF/RARa (Müller-Tidow et 
al., 2004)) have been correlated with an increase in c-Myc expression. Similar increases in 
expression have been observed in chemotherapy-resistant AML as well (Pan et al., 2014), 
indicating that these cancers may rely on c-Myc upregulation to boost growth and cause the 
patient to relapse. In addition to its role in the previously mentioned pathways, c-Myc is also an 
important factor in the maturation of blood cells, and its expression is turned off to allow myeloid 
precursors differentiate. In fact, when myeloid progenitor cells are forced to express c-Myc, their 
ability to differentiate into more specialized cells is lost (Selvakumaran et al., 1996). By 
expressing c-Myc at high levels, AML cells are able to retain their undifferentiated, highly 
proliferative states. The many roles c-Myc has in cancer growth and survival make it an attractive 
target for AML therapy. In fact, c-Myc inhibition has been correlated with a decrease in AML cell 
proliferation and prolonged survival of mice transplanted with AML (Brondfield et al., 2015). 
Reliance on c-Myc overexpression is a common mechanism for many other tumor types as well, 
and an inhibitor of this transcription factor would be useful for treatment of a wide variety of 
cancers (Vita and Henriksson, 2006).  
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1.2.2 Obstacles to c-MYC Inhibition 
Although it is an attractive target, c-Myc has been notoriously difficult to suppress with 
small molecule inhibitors. Neither its interaction with co-factor Max nor its binding to the target 
DNA sequence are easily interrupted with small molecule binding. A few notable exceptions to 
this predicament have been described. The compound 10058-F4 is able to disrupt c-Myc/Max 
heterodimerization and induce apoptosis in AML cells (Huang et al., 2006). However, the Max 
binding surface on c-Myc is flat, large, and lacks distinctive features to target. Due to these 
setbacks, 10058-F4 does not have the specificity needed to be useful in the clinic (Prochownik 
and Vogt, 2010). Cells also gain resistance to protein-targeted compounds by strategically 
mutating the compound’s target site so that it can no longer bind to the protein it was meant to 
inhibit. One way to circumvent these issues is to target the oncogene’s transcription by altering its 
promoter. With this approach, the target is less likely to mutate because promoter alterations are 
more likely to be deleterious to transcription of the entire gene. The compound (+)JQ1 targets the 
transcription of MYC by inhibiting the BET family of proteins (Filippakopoulos and Knapp, 2014). 
BET proteins dock onto acetylated lysines on histone tails and rearrange the chromatin around 
genes to promote their transcription. (+)JQ1 binds these BET proteins and prevents them from 
docking onto histones. This effectively inhibits MYC expression, but it also affects a number of 
other genes regulated by BET proteins. The wide reach of BET inhibition could potentially result 
in significant side effects if (+)JQ1 is used as a therapy for AML. 
1.2.3 Inhibition of MYC through Targeted Stabilization of G-quadruplex DNA structures 
Another method to target MYC transcription is the use of small molecules to stabilize 
DNA secondary structures called G-quadruplexes. These structures are formed when stress from 
negative superhelicity is imposed on guanine-rich stretches of DNA, causing the DNA to form 
tetrads of Hoogsteen base-paired guanine nucleotides to relieve the tension (Bochman et al., 
2012). A few of these tetrads will stack on each other to form a 3D structure called a G-
quadruplex (Fig. 1A). Guanine-rich sequences with the potential to form G-quadruplexes are 
enriched in the promoter regions of many genes involved in cell replication, proliferation, 
apoptosis, and other highly regulated processes with the potential for oncogenesis (Eddy and 
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Maizels, 2006). Often, the presence of a G-quadruplex in a promoter inhibits transcription of its 
associated gene, as is the case for MYC (Brooks and Hurley, 2010) (Fig. 1B). Since the G-
quadruplex structure is in dynamic equilibrium with the promoter’s transcriptionally active single 
stranded and double stranded forms, there exists the opportunity to repress MYC transcription by 
stabilizing the G-quadruplex. This has been achieved previously in vitro using the porphyrin 
molecule TMPyP4 in Burkitt’s Lymphoma cells (Siddiqui-Jain et al., 2002).  
Not only is the G-quadruplex an effective target for gene regulation, but its variable 
structure also creates the opportunity for gene-specific regulation. G-quadruplex structures can 
vary in the length and composition of the loops connecting the tetrads, the number of stacked 
tetrads in the structure, and the orientation of the DNA strands (Brooks et al., 2010). If small 
molecule inhibitors are designed to interact with G-quadruplexes in the variable loops they can 
target specific structures, and consequently specific genes.   
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Figure 1. G-quadruplex Structure and Transcription Regulation Dynamics (A) Example of a G-
quadruplex structure. Tetrads are formed from Hoogsteen base pairing of four guanine 
nucleotides. Two or more tetrads stack to form a G-quadruplex. (B) Diagram of the G-quadruplex 
mediated transcription regulation in the MYC gene. The transcriptionally active dsDNA form of the 
gene is in dynamic equilibrium with the transcriptionally inactive G-quadruplex form of the gene. 
When the G-quadruplex is formed, it recruits the protein Nucleolin to repress gene transcription.   
X	3	
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Finally, G-quadruplexes make excellent targets for oncogene repression because they 
are enriched in the target cancer cells. G-quadruplexes form to relieve stress imposed on the 
DNA by transcriptional unwinding (Sun and Hurley, 2009). When a cancer cell upregulates 
expression of an oncogene, it also increases the amount of time the promoter of that oncogene 
spends in its G-quadruplex form. Therefore, a small molecule inhibitor will be much more likely to 
find its target in a cancer cell than in a normal cell with less transcription of the target gene.  This 
will reduce the off-target effects of G-quadruplex targeting cancer therapies. 
1.3 Research Hypothesis 
This study’s intent is to assess the effect of the G-quadruplex interacting compound 
GQC-05 on AML. This compound has previously been shown to interact with the G-quadruplex in 
the NHE III region of the MYC p2 promoter and repress the gene’s transcription in Burkitt’s 
lymphoma (Brown et al., 2011). Here, the goal is to determine GQC-05’s phenotypic effect in 
different types of AML, as well as its mechanism of action when inducing cell death. Given that 
GQC-05 has other known G-quadruplex targets, another goal is to cross-examine the genome for 
other GQC-05 regulated genes that could represent important targets for AML therapies. The 
hypothesis is that GQC-05 will knock down expression of MYC and induce cell death in AML cells 
with MYC overexpression.  In addition, there are likely other genes targeted by GQC-05 that 
contribute to its cytotoxicity in AML, which could possibly serve as targets for future AML therapy 
development.  
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Chapter 2: Materials and Methods 
2.1 Cell Culture 
All cell lines were authenticated using Short Tandem Repeat (STR) analysis by the 
University of Arizona genomics core. The CMY, CMK, and CMS cell lines were a generous gift 
from Dr. Jeffrey W. Taub, Wayne State University. The KG-1a, HL-60, and MV-4-11 cell lines 
were grown in IMDM media (Corning) supplemented with 20% Fetal Bovine Serum (FBS; Atlas 
Biologicals), 1% L-Glutamine (Caisson Labs), and 1% penicillin/streptomycin (Gibco). The UT-
7epo cells were grown in similar IMDM media that was supplemented with 1 U/mL recombinant 
erythropoietin (rhEPO; R&D Systems). The Molm-13, Kasumi-1, CMY, NB4, TF-1, M-07e, CMK, 
HEL, THP-1, U937, AML-193, and CMS cells were grown in RPMI 1640 (Corning) with 10% FBS 
and 1% penicillin/streptomycin and L-glutamine. The RPMI growth media for TF-1 and M-07e was 
supplemented with 2 ng/mL granulocyte macrophage colony-stimulating factor (GMCSF; R&D 
systems), and the media for AML-193 contained 2 ng/mL GMCSF as well as 5 µg/mL Insulin 
Transferrin Selenium A (ITS; Gibco). PBMCs were isolated from whole blood by density 
centrifugation using Ficoll (GE Life Sciences) and grown in RPMI (10% FBS) supplemented with 
10 ng/mL IL-2 (R&D Systems). All cells were grown at 37°C with 5% CO2. For 6 well plate 
assays, cells were plated at 500,000 cells/mL (KG-1a and TF-1) or 250,000 cells/mL (CMK) with 
4 mL in each well. Cells were allowed to grow overnight before treatment. 
2.2 Antibodies, Primers, and Compounds 
Primary antibodies for c-Myc (Rabbit mAb #5605), Bcl-2 (Rabbit mAb #2870, Mouse mAb 
#15071), and PARP (Rabbit mAb #9532) were purchased from Cell Signaling Technology. The 
GAPDH (Mouse mAb sc-166545) primary antibody was purchased from Santa Cruz 
Biotechnology. Secondary Rabbit and Mouse antibodies were obtained from Jackson 
Immunoresearch. 
Gene specific qPCR primers for c-Myc (Forward: 5’-GCCCACCACCAGCAGCGACTC-3’, 
Reverse: 5’-GCACCTCTTGAGGACCAGTGG-3’), Bcl-2 (Fwd: 5’-
AGTACCTGAACCGGCACCTGC-3’, Rvs: 5’-ACTTGTGGCCCAGATAGGCAC-3’), YWHAZ (Fwd: 
5’-AGAGAAAGCCTGCTCTCTTGC-3’, Rvs: 5’-CGTCTCCTTGGGTATCCGATG-3’), and GAPDH 
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(Fwd: 5’-TGGACCTGACCTGCCGTCTA-3’, Rvs: 5’-AGGAGTGGGTGTCGCTGTTG-3’) were 
obtained from Life Technologies. 
The G-quadruplex interacting compounds GQC-05 and GSA 1103 were kindly provided by Dr. 
Laurence Hurley, School of Pharmacy, University of Arizona. (+)JQ1 and Etoposide were 
obtained from Selleckchem. 
2.3 Drug Dose Response Viability Assays  
For the assays used to determine IC50 values, AML cells (2000 cells/well) or PBMCs 
(10,000 cells/well) were plated on 384 well plates. At 24 hours, cells were treated with various 
drug doses in quadruplicate wells for 72 hours. For GQC-05, treatments were 1:3 serial dilutions 
ranging from 60 µM to 3.05 nM. 5-Azacytidine treatments were previously performed at 1:3 
dilutions ranging from 100 µM to 5.08 nM. For the GQC-05/(+)JQ1 competition assays, GQC-05 
treatments were 1:3 dilutions from 30 µM to 1.52 nM, with (+)JQ1 treatments of 1:4 dilutions 
ranging from 20 µM to 4.9 nM being added as well. After 72 hours of treatment, Cell Titer-Glo® 
(Promega) was added to the cells, and luminescence was read using the PerkinElmer EnVision 
Multilabel Plate Reader. Samples were normalized to untreated controls and dose response 
curves and IC50 values were determined using GraphPad Prism.  
2.4 Western Blots 
Cells were plated at 2,000,000 cells/well in 6 well plates and allowed to grow for 6 or 24 
hours after treatment. Treated cells were washed in PBS (Paradigm) and lysed using RIPA lysis 
buffer (Thermo Fisher) supplemented with 1x Halt Protease & Phosphatase inhibitor cocktail 
(Thermo Fisher). Gel electrophoresis was performed on 15 or 10-well NuPAGE 4-12% Bis-Tris 
gels from Thermo Fisher. Samples were then transferred to Invitrolon PVDF transfer membranes 
(Invitrogen) and blocked overnight in blocking buffer consisting of 1x TBS (Quality Biological) with 
0.1% Tween® 20 (Thermo Fisher) and 5% dehydrated milk. Primary antibodies were used at 
concentrations of 1:1000 except the control gene GAPDH, which was 1:20,000. The secondary 
antibody concentration used was 1:20,000. Blots were imaged after treatment with SuperSignal 
West Pico Chemiluminescent substrate (Thermo Fisher) using the Bio-Rad ChemiDoc™ Imaging 
System. Bands were quantified using the Bio-Rad Image Lab™ software.  
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2.5 Quantitative Polymerase Chain Reaction 
Cells were plated at a concentration of 2,000,000 cells/well in 6 well plates and treated 
for 6 hours. Total RNA was isolated from treated cells using the Qiagen RNeasy® Plus Mini Kit 
as per manufacturer instructions. RNA samples (1 µg) were reverse transcribed using the iScript 
Select cDNA synthesis kit (Bio-Rad). qPCR reactions were prepared in triplicate using iQ SYBR 
GreenSupermix (Bio-Rad) and were performed using a CFX96 Real-Time qPCR Detection 
System (Bio-Rad). Analysis of fold change gene expression was performed on Excel (Microsoft) 
spreadsheets using the Comparative CT method (Schmittgen and Livak, 2008). 
2.6 Luminescence-based Caspase 3/7 Activity Analysis 
Cells were plated in 6 well plates as described above. Aliquots (4 x 25 µl) were taken for 
apoptosis assays and transferred in quadruplicate to 384 well plates. Caspase-Glo® 3/7 
(Promega) was used for the apoptosis assay to determine the activity of caspases 3 and 7, two 
enzymes used by cells during apoptosis. Caspase-Glo® 3/7 contains a substrate that, when 
cleaved by caspase 3 or 7, produces ATP. A thermostable luciferase ATPase also present in the 
solution emits luminescence proportional to the amount of ATP in the sample. Luminescence was 
measured using the EnVision Multilabel Plate Reader (PerkinElmer). 
2.7 Flow Cytometry 
Cells were plated and treated in 6 well plates as described above. After 24 hours of 
treatment, 500,000 cell aliquots of each sample were taken, including 4 aliquots of the 10 µM 
Etoposide positive control and 1 aliquot of each other treatment. Cells were washed twice with 
cell staining buffer (FBS diluted 1:20 in PBS with 1% Sodium Azide), and then resuspended in 50 
µL 5X Annexin binding buffer (Invitrogen) with 5 µM Sytox® Red dead cell stain (life technologies) 
and 1.25 µg/mL Brilliant Violet 421™ Annexin V (Biolegend). Instrument controls included Sytox® 
only, Annexin V only, or unstained sample. Samples were then incubated in the dark at room 
temperature for 15 minutes and diluted 1:10 in PBS prior to analysis. Flow cytometric analysis 
was performed by Dr. Mrinalini Kala of the University of Arizona Translational Flow Cytometry 
Laboratory on a FACSCanto flow cytometry system (BD Biosciences). 
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2.8 Fluorescence Microscopy 
Cells were plated and treated in 6 well plates as described above. After 24 hours of 
treatment, 50 µL cell aliquots of each sample were transferred to wells of a black clear-bottom 96 
well plate. 50 µL of a dye mixture containing 2.5 µg/mL Brilliant Violet 421™ Annexin V and 10 
µM Vybrant™ DyeCycle™ Ruby stain (Invitrogen) in 5x Annexin Binding buffer was added to 
each well. The samples were then allowed to incubate in the dark at room temperature for 20 
minutes before they were imaged using the ImageXpress® Micro XLS Widefield High-Content 
Analysis System (Molecular Devices). Images were then analyzed using Molecular Devices’ 
MetaXpress™ High Content Image Processing Software.  
2.9 RNA-seq Analysis 
Cells were split to 400,000 cells/mL in a T75 culture flask. After 48 hours of growth, they 
were plated in 6 well plates (500,000 cells/mL) and allowed to grow overnight before 6 hours of 
treatment. Total RNA was isolated using the Qiagen RNeasy® Plus Mini Kit. RNA samples were 
then sent to the DNASU sequencing core at Arizona State University for library preparation, 
NextGen sequencing using the Illumina NextSeq500 platform, read alignment to the human 
genome build 38 (GRCh38) toplevel assemble using STAR v2.5.1b, and normalized TPM value 
generation using Cufflinks v2.2.1. TPM values were converted to log2 TPM values for ease of 
handling. Genomics Suite 6.6 (Partek) was used to perform analysis of variance (ANOVA) and 
identify differentially expressed genes with p values < 0.05 and a ≥2 fold difference in gene 
expression between DMSO and GQC-05 treated samples.  
2.10 siRNA Gene Knockdown  
For gene silencing studies, 2 µL of 20 µM siRNA stocks were added to four wells of a six 
well plate. The four siRNA stocks included All Stars Negative Control siRNA (Qiagen), All Stars 
Hs Cell Death Control siRNA (Qiagen), and the c-Myc siRNAs MYC_5 (Qiagen #S100300902) 
and MYC_7 (Qiagen #S102662611). For KG-1a cell assays, 1 mL of diluted transfection reagent 
containing 50 µL Lipofectamine® RNAiMAX transfection reagent (Invitrogen) in 5 mL Opti-MEM™ 
media (Gibco) was added to the four wells with siRNA and one of the two empty wells. 1 mL Opti-
MEM™ was added to the final well. For TF-1 cell assays the diluted transfection reagent 
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contained 25 µL RNAiMAX in 5 mL Opti-MEM™. The plates were incubated at room temperature 
for 30 minutes before addition of 500,000 cells in 1 ml of media to each well.  The media used 
was RPMI with 1% L-Glutamine for TF-1 cells and IMDM with 1% L-Glutamine for KG-1a cells. 
After addition of cells, the plates were placed in the incubator at 37°C, 5% CO2. After 6 hours, 2 
ng/µL GMCSF was added to wells of the TF-1 plates. 24 hours after cell plating, 250 µL of growth 
media with FBS was added to each well. IMDM with 20% FBS and 1% L-Glutamine was used for 
KG-1a cells, and RPMI with 10% FBS and 1% L-Glutamine was used for TF-1 cells. After 48 
hours, aliquots of cells were taken for viability analysis using Cell Titer-Glo® (Promega) and 
caspase activity analysis using Caspase 3/7-Glo® (Promega).  The remaining cells were 
harvested for RNA extraction.  
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Chapter 3: Results 
3.1 Phenotypic Effect of GQC-05 on a Panel of AML Cell Lines 
3.1.1 AML Cell Lines have Variable Sensitivities to GQC-05 
 In order to examine the activity of G-quadruplex interacting drug GQC-05 in AML, drug 
dose response assays were performed on a panel of 16 AML cell lines derived from pediatric and 
adult patients, as well as PBMCs, which were used as a normal cell control.  Viability of the cells 
was measured after 72 hours of treatment with a range of concentrations for either GQC-05 or 5-
Azacytidine, a common therapeutic agent used in AML.  Cell line response to treatment was 
varied (Fig. 2A). GQC-05 was generally more potent, with IC50s ranging from 53 nM to 422 nM 
while 5-Azacytidine IC50s ranged from 199 nM to 4.431 µM (Table 1).   
Cell Line GQC-05 IC50 (nM) 5-Azacytidine IC50 (nM) 
MV-4-11 53 2005 
Molm-13 54 199 
Kasumi-1 57 1547 
UT-7epo 76 2361 
KG-1a 92 4431 
CMY 105 1527 
NB4 153 401 
TF-1 165 1783 
M0-7e 190 879 
CMK 202 739 
HEL 204 1105 
THP-1 224 3497 
U937 315 381 
AML-193 351 2855 
CMS 353 2542 
HL-60 422 3205 
PBMC 191  - 
 
Table 1. IC50 Values of the AML Cell Line Panel Treated with GQC-05 and 5-Azacytidine  
3.1.2 c-Myc and Bcl-2 Protein Expression is Variable in AML Cell Lines 
 Protein expression of the two potential GQC-05 targets, c-Myc and Bcl-2, in the panel of 
16 AML cell lines was analyzed by western blot.  Expression of both c-Myc and Bcl-2 protein was 
widely varied between cell lines with 9 cell lines showing expression of c-Myc protein and 11 cell 
lines expressing Bcl-2 protein (Fig. 2B).  Interestingly only 6 AML cell lines showed expression of 
both proteins. 
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3.1.3 AML Sensitivity to GQC-05 is Correlated to Base c-Myc Protein Expression 
 Quantification of c-Myc and Bcl-2 protein expression in each AML cell line and its 
comparison to the IC50 values of those cells reveals a correlation between high c-Myc protein 
expression and sensitivity to GQC-05 (Fig. 2C). Cancers with high MYC expression are often 
dependent on maintenance of this high level of expression to survive. This correlation indicates 
that c-Myc downregulation may be a mechanism used by GQC-05 to induce cell death in AML 
cells, though the outliers suggest it is likely there is also a secondary mechanism. Bcl-2 protein 
expression appears to have no correlation to GQC-05 sensitivity.  
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Figure 2.  Phenotypic  Effect of GQC-05 on a Panel of AML Cell Lines and Correlation to Protein 
Expression (A) Range of IC50 values in a panel of 16 AML cell lines and a PBMC sample control 
after 72 hr treatment with GQC-05 (right) or a current AML therapy 5-Azacytidine (left). Viability 
was measured using a luminescence assay. Results are an average of four experimental 
replicates. (B) Western blot indicating base c-Myc and Bcl-2 protein expression in the same panel 
of AML lines. (C) Graph indicating a correlation between base c-Myc expression and sensitivity to 
GQC-05 in AML cell lines. No correlation was seen with Bcl-2 expression. Protein expression was 
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quantified by measuring western blot c-Myc band intensity and normalizing it to the GAPDH band 
intensity. 
 
3.2 GQC-05 Downregulates MYC Expression in AML Cell Lines with High Base MYC 
Expression 
3.2.1 c-Myc Protein is Reduced in Four MYC-expressing AML Lines after GQC-05 
Treatment 
 GQC-05 was able to knock down c-Myc protein expression after 6 hours in four cell lines 
that have high c-Myc protein expression: CMK, KG-1a, UT-7epo, and TF-1 (Fig. 3A). Knockdown 
was more significant for GQC-05 treatment than for similar treatment with two other MYC 
inhibitors, the bromodomain inhibitor (+)JQ1 and a second G-quadruplex interacting compound 
GSA 1103. This data shows that GQC-05 is able to knock down c-Myc protein expression in AML 
cells, and further supports c-Myc downregulation as an important factor in the cytotoxicity of 
GQC-05.  
3.2.2 GQC-05 Reduces MYC mRNA and Protein in KG-1a, CMK, and TF-1 Cell Lines 
Expression of MYC mRNA in the MYC expressing cell lines KG-1a, CMK, and TF-1 was 
analyzed after 6 hours of GQC-05 treatment. All three cell lines show a decrease in MYC mRNA 
expression after treatment with GQC-05, though KG-1a showed the strongest response (Fig. 3B). 
When the same set of cell samples were analyzed via western blot, a downregulation of c-Myc 
protein was observed as well (Fig. 3C). GQC-05’s ability to knock down both c-Myc protein and 
MYC mRNA suggests that it may be inhibiting transcription of the gene rather than translation.		 	
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Figure 3. GQC-05 Induces Loss of c-Myc in AML Lines with High MYC Expression (A) Western 
blot showing loss of c-Myc protein in AML cell lines after 6 hr treatment with the MYC inhibitors 
GQC-05, GSA 1103, and (+)JQ1. GQC-05 and (+)JQ1 were at 1 µM while GSA 1103 was at 3 
µM. (B) qPCR analysis of AML cells treated 6 hr with GQC-05 shows loss of MYC mRNA after 
treatment. KG-1a and CMK results are an average of three experimental replicates, and TF-1 
results are an average of two. (C) Western blot showing loss of c-Myc protein in AML cells after 6 
hr treatment with GQC-05. qPCR and western blot analysis of c-Myc loss were done on the same 
set of samples.  
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3.3 siRNA Mediated Knockdown of MYC Reduces Viability and Induces Apoptosis in 
Sensitive AML Cell Lines to a Lesser Degree than GQC-05 
 KG-1a and TF-1 cells were transfected with two MYC specific siRNAs as well as positive 
and negative control siRNAs for 48 hours. Only MYC specific siRNA MYC_5 was able to reduce 
cell viability, with a viability loss of only 13% in the GQC-05 sensitive cell line KG-1a (Fig. 4A). 
However, both MYC specific siRNA MYC_5 and MYC_7 were able to knock down expression of 
MYC mRNA in both KG-1a and TF-1 (Fig. 4B). Furthermore, apoptosis was induced by MYC 
knockdown in KG-1a cells as evidenced by the increase in caspase 3/7 activity with MYC specific 
siRNA treatment. No such induction was seen with TF-1 cells (Fig. 4C).  
18	
	
A 
 
 
 
 
B 
 
 
 
 
C 
 
 
 
 
 
Figure 4. siRNA Knockdown of MYC in AML Cells Reduces Viability and Induces Apoptosis in 
GQC-05 Sensitive AML Cells (A) Viability data after 48 hour siRNA treatment in KG-1a and TF-1 
indicates a 13% loss of viability in KG-1a cells treated with MYC specific siRNA MYC_5. (B) 
qPCR analysis shows siRNA mediated knockdown of MYC by both MYC specific siRNAs MYC_5 
and MYC_7 in KG-1a and TF-1 after 48 hours. (C) Caspase 3/7 activity is increased in KG-1a 
cells treated 48 hours with MYC specific siRNA, but not in TF-1 cells. All results for Figure 4 
include at least two experimental replicates.  
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3.4 GQC-05 Induces Apoptosis in Sensitive AML Cell Lines 
KG-1a, CMK, and TF-1 cells were analyzed for induction of apoptosis after 24 hours of 
treatment with GQC-05. Etoposide, a chemotherapy clinically used to treat AML, was used as an 
apoptosis positive control. Apoptosis was induced in KG-1a cells treated with GQC-05, as 
evidenced by the increase in caspase 3/7 activity (Fig. 5A), PARP cleavage (Fig. 5B), and 
Annexin V staining (Fig. 5C+D). It is also apparent that c-Myc downregulation is induced in 
conjunction with PARP cleavage in KG-1a cells. However, both of the less sensitive cell lines, 
CMK and TF-1, show that c-Myc protein expression is no longer downregulated by GQC-05 at 24 
hours, and there is little increase in caspase 3/7 activity, PARP cleavage, or Annexin V staining 
after GQC-05 treatment. This suggests that CMK and TF-1 have some mechanism of resistance 
to GQC-05 mediated knockdown of c-Myc and induction of apoptosis.  
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Figure 5. GQC-05 Induces Apoptosis in Sensitive AML Cell Lines. (A) Caspase 3/7 activity in KG-
1a, TF-1, and CMK cells after 24 hour treatment. Apoptosis was induced in the GQC-05 sensitive 
KG-1a cells, but it was not significantly induced in the more resistant CMK and TF-1 cells. 
Etoposide was used as a positive apoptosis control. KG-1a results are an average of three 
experimental replicates. All TF-1 and CMK results but the 600 nM GQC-05 treatment are an 
average of two experimental replicates. (B) The same treated cells were analyzed for PARP 
cleavage and c-Myc protein expression by western blot analysis. PARP cleavage and c-Myc 
protein loss were only significantly induced in the KG-1a cells. (C) Annexin V/ Dead Cell 
Apoptosis Assay of KG1-a cells treated with GQC-05.  Analysis was done by flow cytometry using 
Brilliant Violet Annexin V (x-axis) and Sytox Red (y-axis) staining in the same treated cells. 
Annexin staining and cell death increased with GQC-05 treatment in KG-1a cells, but not 
significantly in CMK or TF-1 cells. (D) Fluorescence microscopy analyzing Annexin V (blue) 
staining in KG-1a cells.  The red Vybrant DyeCycle Ruby stain is a cell permeable nucleus 
marker indicating the location of all cells. These images highlight the increase of Annexin V 
binding to KG-1a cells after treatment with GQC-05.  
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3.5 Combined Treatment of AML with GQC-05 and (+)JQ1 Reveals an Antagonistic Effect 
 In order to examine the effect of a GQC-05 and (+)JQ1 combination treatment on AML 
cells, KG-1a cells were treated with a range of GQC-05 concentrations in combination with a 
range of (+)JQ1 concentrations. After 72 hours, viability was measured to determine the 
compound combination’s effect on cell viability. Dose response curves revealed that addition of 
(+)JQ1 to the cells increased the IC50 of GQC-05 (Fig. 6A). When comparing the loss of viability 
after treatment with either individual compound to that of the combination treatment, it becomes 
apparent that the two compounds are antagonistic (Fig. 6B).  
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Figure 6. GQC-05 and (+)JQ1 Antagonism (A) 72 hr treatment of KG-1a cells with combinations 
of various doses of GQC-05 and (+)JQ1 show a decrease in cytotoxicity of GQC-05 when (+)JQ1 
is also added. The IC50 values of GQC-05 increase with the (+)JQ1 dose. Viability was 
measured using a luminescence assay. Two replicates of this experiment produced similar 
results. (B) Viability in cells treated with either GQC-05, (+)JQ1, or a combination of the two was 
normalized to viability of untreated cells. This analysis highlights a much larger drop in viability in 
the two single treatments compared to the dual treatment.  
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3.6 RNA-seq Reveals Additional Potential Targets of GQC-05 
3.6.1 Expression of 17 Potentially G-quadruplex Regulated Genes are Modulated by  
GQC-05  
 RNA-seq was performed to better understand the global effect of GQC-05 treatment on 
AML cells. After 6 hours of treatment with either DMSO (vehicle control) or GQC-05, total mRNA 
was isolated from the samples. RNA-seq was performed on each sample, and log2 TPM values 
were generated for 19,873 protein-coding genes. Of these genes, 947 had a fold change in 
expression of ≥2 between the DMSO and GQC-05 treated samples, and were considered to be 
significantly modulated by GQC-05. The three DMSO samples clustered separately from the 
GQC-05 samples when hierarchical clustering analysis was applied based on the expression of 
the 947 genes, indicating a high experimental reproducibility (Fig. 7A). To separate genes that 
may be amplified in the cell or have a greater impact on cellular processes, a list of 694 more 
highly expressed genes with at least one log2 TPM value of ≥3 was generated. Genes on either 
list were cross-referenced with a list of 209 genes known to be associated with high G-quadruplex 
forming potential (Eddy and Maizels, 2006; Lam et al., 2013) (Fig. 7B). The 17 genes that were 
modulated by GQC-05 and known to have G-quadruplex forming potential were considered to be 
potential targets of GQC-05. Most of the 17 genes were downregulated by GQC-05, but three 
genes were upregulated (Fig. 7C).  The significance of the gene expression modulation is 
highlighted by the relatively constant expression of the housekeeping genes YWHAZ and GAPDH 
(Fig. 7D).  
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Figure 7. RNA-seq Analysis of KG-1a Treated with GQC-05 Introduces 17 Potential Targets of 
GQC-05. (A) Hierarchical clustering analysis of the 947 genes determined to have a ≥2 fold 
difference in expression between the DMSO (vehicle) and GQC-05 treated samples. (B) Diagram 
demonstrating the overlap between three sets of genes: 209 genes known in the literature to 
have high G-quadruplex forming potential (red), the 947 genes differentially expressed between 
DMSO and GQC-05 treated RNA-seq samples (green), and 694 genes from the previous set with 
one log2 TPM ≥3 (blue). (C) Relative expression of the 17 genes of interest in each of the RNA-
seq samples highlights which genes are upregulated and which are downregulated by GQC-05. 
DMSO GQC-05 
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(D) Graphs of the log2 TPM values from each RNA-seq sample for 6 genes of interest known to 
have cancer involvement and the 2 housekeeping genes YWHAZ and GAPDH. 
 
3.6.2 Four Oncogenes with Significant Expression in KG-1a Cells are Downregulated by 
GQC-05  
 8 of the 17 genes modulated by GQC-05 are known to be oncogenic  (Eddy and Maizels, 
2006; Freier et al., 2006; Heimann et al., 2001; Marcucci et al., 2008; Pogue-Geile et al., 2006; 
Stein et al., 2012; Vega and Ridley, 2008; Wei et al., 2013), and 6 of them were downregulated. 
Of those 6 genes, 4 had a TPM of ≥3 in at least one sample: MYC, NOTCH1, PIM1, and RHOU 
(Table 2).   The International Cancer Genome Consortium (ICGC) Data Portal was used to gather 
pathway involvement data for each of the 17 genes.   
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Gene TPM ≥3 Δ Expression Cancer Involvement Pathway Involvement 
ASPSCR1 No Down Oncogene (fusion: TFE3) 
Membrane trafficking/ 
Glucose metabolism 
CDKN2B No Up Tumor suppressor Cell cycle 
PALLD No Up Oncogene Cytoskeleton/ Cell mobility 
SHANK2 No Down Upregulated Protein-protein interactions at synapses 
SLC12A7 No Down - Ion transport 
VEGFA No Down Oncogene Endothelial growth signaling 
ZFPM1 No Down Upregulated Erythroid/ megakaryocytic cell differentiation 
CEP19 Yes Down - Centrosome protein 
FGF18 Yes Up Oncogene Cell growth/ invasion 
INSIG1 Yes Down - Lipid metabolism 
MYC Yes Down Oncogene Transcription (multiple pathways) 
NOTCH1 Yes Down Oncogene Cell differentiation/ Development 
PIM1 Yes Down Oncogene Cell proliferation/ Survival 
PRMT6 Yes Down Oncogene Chromatin rearrangement/ Cell growth 
RHOU Yes Down Oncogene Cytoskeleton/ Cell migration 
STX3 Yes Down - Membrane trafficking 
XPO6 Yes Down - Nuclear transport 
	
Table 2. Expression and Gene Function of Each of the 17 GQC-05 Modulated Genes.  
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Chapter 4: Discussion 
4.1 Selective Cytotoxicity of GQC-05 on a Subset of AML Cell Lines 
 Though many cases of AML have been linked to MYC overexpression and dependency, 
a varied cellular response to the known MYC inhibitor GQC-05 was expected due to the genetic 
heterogeneity of AML as a disease (Li et al., 2016). In line with this reasoning, the IC50 values of 
GQC-05 observed from the panel of 16 AML cell lines ranged from 199 nM to 4.431 µM. These 
differential IC50s indicated that GQC-05 may be an effective treatment for a subset of AML cell 
types. To determine if this subset is sensitive because of its expression of a gene targeted by 
GQC-05, the base expression of both BCL2 and MYC were analyzed. These two genes were 
chosen because GQC-05 is known to bind the G-quadruplexes in their promoters in vitro (Brown 
et al., 2011). BCL2 expression did not correlate with GQC-05 sensitivity, but the slight correlation 
of MYC expression to GQC-05 sensitivity suggests that MYC inhibition may play a role in the 
cytotoxicity of GQC-05. However, the correlation is not strong enough to suggest that MYC 
inhibition is GQC-05’s only mechanism of action, and there is a possibility that it may be targeting 
other G-quadruplex regulated genes. 
4.2 Mechanism of Action of GQC-05 
4.2.1 MYC Expression Knockdown 
GQC-05 was shown to knock down MYC expression more completely in the sensitive 
AML lines KG-1a and UT-7epo than in the more resistant cell lines CMK and TF-1. GQC-05 also 
outperformed MYC inhibitors GSA 1103 and (+)JQ1 in MYC inhibition in the more sensitive cell 
lines, while all three inhibitors showed similar inhibition in CMK and TF-1. This discrepancy may 
be due to the expression of another GQC-05 target in the sensitive cells. When this alternative 
target is inhibited, MYC downregulation could be strengthened. This theory is further supported 
by the inability of MYC specific siRNA to reduce cell viability or induce apoptosis as significantly 
as GQC-05. While this may be due to the incomplete knockdown of MYC by the siRNA, the 
reduction in KG-1a cell viability is only 13% while c-Myc mRNA levels are knocked down 30%. 
This suggests that incomplete knockdown may not entirely explain the reduced potency, and 
another gene target needs to be downregulated for the full effect.  
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4.2.2 Induction of Apoptosis 
 GQC-05 stimulates an apoptotic pathway to kill sensitive AML cell lines, as evidenced by 
a significant increase in caspase 3/7 activity, PARP cleavage, and Annexin V staining after 
treatment. However, apoptosis is not induced in the less sensitive AML cell lines CMK and TF-1, 
and expression of c-Myc protein in these cell lines at 24 hours has rebounded. This suggests 
that, because GQC-05 is not able to knock down MYC expression as significantly in some AML 
cell lines, MYC expression is able to rebound before apoptosis can be induced. Again, this could 
be due to GQC-05 mediated inhibition of a secondary target that is partially responsible for MYC 
upregulation in sensitive cell lines. 
4.2.3 Antagonism with MYC Inhibitor (+)JQ1 
 The cytotoxicity of GQC-05 in KG-1a cells is reduced when the MYC inhibitor (+)JQ1 is 
added into the mix. Antagonism between these two MYC inhibitors offers insight into the 
molecular mechanism of GQC-05. (+)JQ1 is a bromodomain inhibitor that represses MYC by 
inhibiting the protein responsible for rearranging the chromatin near MYC into a transcriptionally 
favorable form (Filippakopoulos and Knapp, 2014). GQC-05, on the other hand, inhibits MYC 
through G-quadruplex stabilization, and the MYC-repressive G-quadruplex forms from single 
stranded DNA. It is possible that (+)JQ1 and GQC-05 are competing for double stranded and 
single stranded forms of the same stretch of nucleotides, which leads to an antagonistic 
combinatory effect. Another explanation for this antagonism could be a secondary GQC-05 target 
that, when repressed, interferes with the pathway (+)JQ1 targets to repress MYC expression. 
4.3 Potential Targets of GQC-05 
 RNA-seq analysis of GQC-05 treated cells identified several genes that were 
downregulated by the compound.  The three non-MYC potential targets of GQC-05 with 
oncogenic significance include the transmembrane receptor gene NOTCH1, the signal 
transduction kinase gene PIM1, and the rho GTPase gene RHOU. 
4.3.1 NOTCH1 
 The NOTCH1 gene codes for a transmembrane receptor protein involved in development 
and T-cell differentiation. When Notch-1 proteins receive a signal, an intracellular fragment of the 
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protein called the ICN detaches, translocates to the nucleus, and directly activates the 
transcription of MYC (Fig. 8), making it a potent oncogene when misregulated  (Weng et al., 
2006). Notch-1 activating mutations that prolong protein half-life or enable ligand-independent 
cleavage of the ICN segment are commonly identified in T-ALL, but are also present in some 
instances of AML (Tohda, 2014). Expression of NOTCH1 has been shown to vary in AML 
samples and cell lines, with some having high expression while others have little (Kanamori et al., 
2012). A dual inhibition of both NOTCH1 and MYC in MYC-dependent AML cell lines that express 
both genes could have a much stronger MYC expression knockdown effect than direct MYC 
inhibition alone. NOTCH1 is a promising target for many blood cancers, and G-quadruplex 
mediated inhibition of this gene would be a novel and effective way to treat these diseases. 
4.3.2 PIM1 
Pim-1 is a Ser/Thr protein kinase encoded by the PIM1 gene. This kinase has been 
shown to phosphorylate the c-Myc protein, leading to an increase in the stability and amount of c-
Myc in the cell (Zhang et al., 2008) (Fig. 8). PIM1 has been shown to be upregulated and 
oncogenic in some AML cases, particularly those with the FLT3-ITD fusion  (Kim et al., 2005). 
Inhibition of PIM1 expression by GQC-05 could explain the high sensitivity of FLT3-ITD positive 
cell lines MV-4-11 and Molm 13 to GQC-05 despite their low expression of c-Myc protein. This 
gene is also an important target because the FLT3-ITD mutation in AML has been detected in 
around 35% of AML cases, and is generally an indicator of poor prognosis (Kindler et al., 2010). 
An effective treatment for this subset of AML is sorely needed. 
4.3.3 RHOU 
The protein product of RHOU is a Rho GTPase capable of inducing reentry into the cell 
cycle. RhoU, also known as Wrch-1, is capable of activating the protein kinase PAK-1 (Tao et al., 
2001). The PAK-1 protein is an important target in AML, and its inhibition leads to apoptosis, 
differentiation, reduction in AML progression, and downregulation of MYC (Pandolfi et al., 2015) 
(Fig. 8). GQC-05 mediated transcriptional inhibition of the PAK-1 activator RhoU could potentially 
decrease the amount of active PAK-1 in the cell enough to induce apoptosis and MYC 
downregulation. This indirect inhibition of PAK-1 could be useful for treatment of other cancer 
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types as well, including breast cancer (Shrestha et al., 2012), bladder cancer (Redelman-Sidi et 
al., 2013), and non-small cell lung cancer (Mortazavi et al., 2015).  
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Figure 8. c-Myc Linked Pathways Potentially Targeted by GQC-05: Pathway connections of the 
three genes potentially downregulated by GQC-05 (NOTCH1, PIM1, and RHOU) to MYC 
regulation and c-Myc stability. After a signal is received, the ICN segment of the Notch-1 protein 
is cleaved and translocates to the nucleus, where it directly binds MYC and facilitates its 
transcription. RhoU protein activates the PAK-1 kinase, which through an unknown mechanism 
upregulates MYC expression. Pim-1 is capable of phosphorylating and stabilizing the c-Myc 
protein.  
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4.4 Conclusions and Future Experiments 
 MYC inhibition by GQC-05 is integral to the compound’s cytotoxicity and ability to induce 
apoptosis in AML. Though direct inhibition of MYC through stabilization of the gene’s NHEIII G-
quadruplex is certainly likely, it is also probable that downregulation of NOTCH1, PIM1, RHOU, or 
a combination of the three by GQC-05 may be needed to knock down MYC significantly enough 
to induce apoptosis. Functional validation of the role of these genes in AML will need to be 
performed. Future testing of AML cell lines for sensitivity to single gene or combination 
knockdown of these four genes by RNAi or CRISPR could determine which genes are vital for 
growth and survival of AML cells. After identification of the most important GQC-05 targets, 
compound libraries could be screened to identify new compounds with structural similarity to 
GQC-05 that are more specific for the genes of interest. Identification of these compounds is 
crucial for identification of a compound with reduced toxicity that can be progressed to animal 
models and potentially clinical trials.  
Another area of interest for future studies would be the characterization of any regulatory 
G-quadruplexes that form in the promoter regions of NOTCH1, PIM1, or RHOU. A better 
understanding of the regulation of these genes could prove beneficial for more advanced design 
of gene specific inhibitors that could benefit patients diagnosed with one of the myriad of diseases 
driven by these oncogenes.  
From the studies outlined in this thesis, it can be concluded that MYC inhibition through 
GQC-05 mediated G-quadruplex stabilization is a promising avenue for the development of 
therapies for AML and potentially other cancers. 
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